Brookdale Senior Living (NYSE:BKD – Get Free Report) and GeneDx (NASDAQ:WGS – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.
Earnings and Valuation
This table compares Brookdale Senior Living and GeneDx”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Brookdale Senior Living | $3.19 billion | 0.76 | -$262.69 million | ($0.58) | -17.47 |
| GeneDx | $427.54 million | 4.53 | -$21.02 million | ($3.64) | -17.85 |
Risk & Volatility
Brookdale Senior Living has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, GeneDx has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500.
Institutional and Insider Ownership
61.7% of GeneDx shares are held by institutional investors. 0.7% of Brookdale Senior Living shares are held by company insiders. Comparatively, 25.2% of GeneDx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Brookdale Senior Living and GeneDx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Brookdale Senior Living | -4.53% | -15,050.32% | -1.09% |
| GeneDx | -23.41% | 4.12% | 2.26% |
Analyst Ratings
This is a summary of current ratings for Brookdale Senior Living and GeneDx, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Brookdale Senior Living | 1 | 0 | 5 | 2 | 3.00 |
| GeneDx | 1 | 1 | 7 | 0 | 2.67 |
Brookdale Senior Living presently has a consensus target price of $17.40, indicating a potential upside of 71.70%. GeneDx has a consensus target price of $90.86, indicating a potential upside of 39.87%. Given Brookdale Senior Living’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Brookdale Senior Living is more favorable than GeneDx.
Summary
GeneDx beats Brookdale Senior Living on 8 of the 14 factors compared between the two stocks.
About Brookdale Senior Living
Brookdale Senior Living Inc. owns, manages, and operates senior living communities in the United States. It operates in three segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRCs). The Independent Living segment owns or leases communities comprising independent and assisted living units in a single community that are primarily designed for middle to upper income seniors. The Assisted Living and Memory Care segment owns or leases communities consisting of freestanding, multi-story communities and freestanding, single-story communities, which offer housing and 24-hour assistance with activities of daily living for the Company’s residents. This segment also operates memory care communities for residents with Alzheimer’s and other dementias. The CCRCs segment owns or leases communities that provides various living arrangements, such as independent and assisted living, memory care, and skilled nursing; and services to accommodate various levels of physical ability and healthcare needs. It also manages communities on behalf of others. Brookdale Senior Living Inc. was incorporated in 2005 and is headquartered in Brentwood, Tennessee.
About GeneDx
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.
Receive News & Ratings for Brookdale Senior Living Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brookdale Senior Living and related companies with MarketBeat.com's FREE daily email newsletter.
